| Literature DB >> 2904131 |
R Leblanc1, S Gauthier, M Gauvin, R Quirion, R Palmour, H Masson.
Abstract
We infused somatostatin and its long-acting analogue (SMS 201-995) into the intracranial subarachnoid space of eight monkeys. Chronic infusions of SMS 201-995 produced marked neurotoxic effects characterized by truncal ataxia, dysmetria, and severe bradykinesia, with normal level of consciousness. Subcutaneous injection of apomorphine, a dopaminergic agonist, promptly reversed these effects. Further studies are required before intrathecal somatostatin replacement therapy can be offered to patients with Alzheimer's disease.Entities:
Mesh：
Substances：
Year: 1988 PMID： 2904131 DOI： 10.1212/wnl.38.12.1887
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910